FR2854073B1 - Composition pharmaceutique solide comprenant un agoniste du recepteur s1p et un alcool de sucre - Google Patents

Composition pharmaceutique solide comprenant un agoniste du recepteur s1p et un alcool de sucre

Info

Publication number
FR2854073B1
FR2854073B1 FR0450692A FR0450692A FR2854073B1 FR 2854073 B1 FR2854073 B1 FR 2854073B1 FR 0450692 A FR0450692 A FR 0450692A FR 0450692 A FR0450692 A FR 0450692A FR 2854073 B1 FR2854073 B1 FR 2854073B1
Authority
FR
France
Prior art keywords
pharmaceutical composition
receptor agonist
sugar alcohol
solid pharmaceutical
oral administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0450692A
Other languages
English (en)
French (fr)
Other versions
FR2854073A1 (fr
Inventor
Tomoyuki Oomura
Madhusudhan Pudipeddi
Colleen Ruegger
Alan Edward Royce
Masaki Sasaki
Tokuhiro Tamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Mitsubishi Tanabe Pharma Corp
Original Assignee
Novartis AG
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2854073(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG, Mitsubishi Pharma Corp filed Critical Novartis AG
Publication of FR2854073A1 publication Critical patent/FR2854073A1/fr
Application granted granted Critical
Publication of FR2854073B1 publication Critical patent/FR2854073B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
FR0450692A 2003-04-08 2004-04-06 Composition pharmaceutique solide comprenant un agoniste du recepteur s1p et un alcool de sucre Expired - Lifetime FR2854073B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08

Publications (2)

Publication Number Publication Date
FR2854073A1 FR2854073A1 (fr) 2004-10-29
FR2854073B1 true FR2854073B1 (fr) 2008-03-14

Family

ID=32326722

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0450692A Expired - Lifetime FR2854073B1 (fr) 2003-04-08 2004-04-06 Composition pharmaceutique solide comprenant un agoniste du recepteur s1p et un alcool de sucre
FR11C0036C Active FR11C0036I2 (fr) 2003-04-08 2011-09-08 Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR11C0036C Active FR11C0036I2 (fr) 2003-04-08 2011-09-08 Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre

Country Status (41)

Country Link
US (11) US20060275357A1 (Direct)
EP (5) EP2008650A3 (Direct)
JP (3) JP5495467B2 (Direct)
KR (3) KR20110005320A (Direct)
CN (2) CN1767819B (Direct)
AR (3) AR043987A1 (Direct)
AT (3) AT501681B1 (Direct)
AU (1) AU2004228929B2 (Direct)
BE (2) BE1015972A5 (Direct)
BR (1) BRPI0409250B8 (Direct)
CA (2) CA2707750A1 (Direct)
CL (2) CL2004000745A1 (Direct)
CY (3) CY1110260T1 (Direct)
DE (4) DE122011100047I1 (Direct)
DK (2) DK2316431T3 (Direct)
EC (1) ECSP056090A (Direct)
ES (3) ES2556947T3 (Direct)
FR (2) FR2854073B1 (Direct)
GB (1) GB2400318B (Direct)
GR (1) GR1005052B (Direct)
HR (3) HRP20050886B1 (Direct)
HU (2) HUE028247T2 (Direct)
IL (3) IL170888A (Direct)
IS (2) IS2682B (Direct)
IT (1) ITMI20040682A1 (Direct)
LU (1) LU91867I2 (Direct)
MA (1) MA27729A1 (Direct)
MX (1) MXPA05010860A (Direct)
MY (1) MY141249A (Direct)
NO (4) NO329332B1 (Direct)
NZ (3) NZ542622A (Direct)
PE (5) PE20090743A1 (Direct)
PL (2) PL2316431T3 (Direct)
PT (1) PT1613288E (Direct)
RU (5) RU2358716C2 (Direct)
SG (1) SG175449A1 (Direct)
SI (2) SI2316431T1 (Direct)
TN (1) TNSN05256A1 (Direct)
TW (1) TWI332847B (Direct)
WO (1) WO2004089341A1 (Direct)
ZA (1) ZA200507394B (Direct)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1773307E (pt) * 2004-07-30 2015-01-14 Novartis Ag Formulações de compostos à base de 2-amino-1,3- propanodiol
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
AU2006289100B2 (en) * 2005-09-09 2010-07-22 Novartis Ag Treatment of autoimmune diseases
EP1948678B1 (en) 2005-11-09 2013-05-01 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
ES2415632T3 (es) 2006-06-19 2013-07-26 Onyx Therapeutics, Inc. Epoxicetonas peptídicas para la inhibición del proteosoma
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
KR20090057399A (ko) * 2006-09-26 2009-06-05 노파르티스 아게 Ｓ１ｐ 조정제를 포함하는 제약 조성물
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
CA2680039C (en) 2007-03-29 2015-05-26 Daiichi Sankyo Company, Limited Pharmaceutical composition comprising edoxaban, an anticoagulant
EP2612865A3 (en) 2007-10-04 2014-03-19 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
EP3120833A1 (en) * 2007-10-12 2017-01-25 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
KR101653071B1 (ko) 2008-03-17 2016-08-31 액테리온 파마슈티칼 리미티드 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생
WO2009152922A1 (de) * 2008-06-20 2009-12-23 Merck Patent Gmbh Direkt verpressbare und schnell zerfallende tablettenmatirx
EP2303250A1 (en) 2008-06-20 2011-04-06 Novartis AG Paediatric compositions for treating1 multiple sclerosis
CA2735037C (en) * 2008-09-04 2016-07-12 Cargill Incorporated Tabletting of erythritol
CN102256616A (zh) 2008-10-21 2011-11-23 欧尼斯治疗公司 与肽环氧酮的联合疗法
AU2013100531B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
CN102256933A (zh) 2008-11-11 2011-11-23 诺瓦提斯公司 芬戈莫德的盐
AU2009315736B2 (en) * 2008-11-11 2013-08-29 Novartis Ag Crystalline forms of fingolimod HCL
CA2747427C (en) 2008-12-17 2015-10-13 Daiichi Sankyo Company, Limited Method for producing diamine derivative
WO2010082531A1 (ja) 2009-01-13 2010-07-22 第一三共株式会社 活性化血液凝固因子阻害剤
CN102348688B (zh) 2009-03-10 2014-07-09 第一三共株式会社 用于制备二胺衍生物的方法
JP5652879B2 (ja) 2009-03-13 2015-01-14 第一三共株式会社 光学活性なジアミン誘導体の製造方法
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
MY155256A (en) * 2009-06-18 2015-09-30 Daiichi Sankyo Co Ltd Pharmaceutical composition having improved solubility
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
MA34133B1 (fr) 2010-03-01 2013-04-03 Onyx Therapeutics Inc Composes pour inhibiteurs de l'immunoproteasome
ES2601884T3 (es) 2010-03-19 2017-02-16 Daiichi Sankyo Company, Limited Procedimiento para mejorar la capacidad de disolución de un anticoagulante
ES2560955T3 (es) 2010-03-19 2016-02-23 Daiichi Sankyo Company, Limited Cristal de derivado de diamina y procedimiento de producción del mismo
US20130095177A1 (en) * 2010-04-22 2013-04-18 Ratiopharm Gmbh Method of preparing an oral dosage form comprising fingolimod
EP2589590B1 (en) 2010-07-02 2016-12-28 Daiichi Sankyo Company, Limited Process for preparation of optically active diamine derivative salt
US9266816B2 (en) 2010-11-25 2016-02-23 Shilpa Medicare Limited Fingolimod polymorphs and their processes
HRP20191842T1 (hr) 2011-01-07 2019-12-27 Novartis Ag Formulacije imunosupresiva
WO2012100043A2 (en) 2011-01-19 2012-07-26 Pathlogica LLC Controlled release oral pharmaceutical dosage forms comprising mgbg
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
WO2013019872A1 (en) 2011-08-01 2013-02-07 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
JPWO2013022059A1 (ja) 2011-08-10 2015-03-05 第一三共株式会社 ジアミン誘導体含有医薬組成物
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
ES2859553T3 (es) 2013-01-08 2021-10-04 Pathologica Llc Mitoguazona para el tratamiento de esclerosis múltiple progresiva
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
WO2014175287A1 (ja) * 2013-04-26 2014-10-30 国立大学法人 京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
WO2013190151A1 (en) * 2013-05-13 2013-12-27 Synthon B.V. Pharmaceutical composition comprising fingolimod
CA2920758A1 (en) * 2013-07-29 2015-02-05 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
CN106794159A (zh) * 2014-08-22 2017-05-31 广东东阳光药业有限公司 一种芬戈莫德固体组合物及其制备方法
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
CN107530301A (zh) * 2015-01-20 2018-01-02 汉达医药有限责任公司 稳定的固体芬戈莫德剂型
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
WO2018178744A1 (en) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) * 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
US11298412B2 (en) 2020-07-16 2022-04-12 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for prophylaxis and/or therapy of coronaviridae infection
JP2024506825A (ja) * 2021-01-28 2024-02-15 プリオセラ エスエーエス Ｓ１ｐ受容体調節剤による処置の方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
ES2126658T3 (es) * 1992-10-21 1999-04-01 Yoshitomi Pharmaceutical Compuesto de 2-amino-1,3-propanodiol e inmunosupresor.
DE69524962D1 (de) 1994-08-22 2002-02-14 Welfide Corp Benzolderivate und deren medizinische verwendung
ATE279185T1 (de) 1995-12-28 2004-10-15 Mitsubishi Pharma Corp 2-amino-2-(2-(4-octylphenyl)ethyl)propan-1,3-di l enthaltendes arzneimittel zur topischen anwendung zur behandlung von erkrankungen die durch eine störung des immunsystems hervorgerufen werden
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
JP2002241272A (ja) 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
DK0990440T3 (da) * 1997-02-27 2009-02-23 Novartis Ag Farmaceutisk sammensætning indeholdende 2-amino-2[2-(4-octylphenyl)-ethyl]-propan-1,3-diol, en lecithin og et saccharid
PT1002792E (pt) * 1997-04-04 2004-12-31 Mitsubishi Pharma Corp Compostos de 2-aminopropano-1,3-diol, sua utilizacao medicinal e intermediariosda sintese dos mesmos
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
EP1195165A4 (en) * 1999-07-12 2005-08-10 Ono Pharmaceutical Co FIBROSIS INHIBITORS CONTAINING THE ACTIVE INGREDIENT OF SPHINGOSINE A PHOSPHATE OR ITS RECEPTOR AGONISTS
NZ533997A (en) 2000-07-13 2005-11-25 Sankyo Co Amino alcohol derivatives
AU2001285331B2 (en) 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
PL367348A1 (en) 2001-03-26 2005-02-21 Novartis Ag 2-amino-propanol derivatives
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
JPWO2003020313A1 (ja) 2001-09-04 2004-12-16 小野薬品工業株式会社 スフィンゴシン−１−リン酸受容体調節剤からなる呼吸器疾患治療剤
JP4217620B2 (ja) 2001-09-27 2009-02-04 杏林製薬株式会社 ジアリールスルフィド誘導体とその付加塩及び免疫抑制剤
EP1431275B1 (en) 2001-09-27 2010-04-07 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
CA2472715A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
EP1513522A2 (en) 2002-01-18 2005-03-16 Sri International Methods of treating conditions associated with an edg receptor
EP1469863A2 (en) 2002-01-18 2004-10-27 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
EP1772145B1 (en) * 2004-07-16 2011-03-23 Kyorin Pharmaceutical Co., Ltd. Method of effectively using medicine and method concerning prevention of side effect

Also Published As

Publication number Publication date
JP5543298B2 (ja) 2014-07-09
CN1767819A (zh) 2006-05-03
NZ592339A (en) 2012-09-28
EP2316431B1 (en) 2015-09-30
EP2008650A3 (en) 2011-04-27
GR20040100121A (el) 2004-12-17
BRPI0409250B1 (pt) 2017-07-11
CN1767819B (zh) 2010-07-28
NO2011016I2 (no) 2012-08-27
IL242037A0 (en) 2015-11-30
HRP20100601B1 (hr) 2016-12-02
IS2682B (is) 2010-10-15
IL170888A (en) 2010-06-16
HRP20100600A2 (hr) 2011-03-31
HRP20050886B1 (en) 2011-01-31
DE102004016947A1 (de) 2004-10-21
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
US8324283B2 (en) 2012-12-04
ES2556947T3 (es) 2016-01-21
HUS1100016I1 (hu) 2016-08-29
MY141249A (en) 2010-03-31
DK2316431T3 (en) 2016-01-11
US20200237690A1 (en) 2020-07-30
ES2228282A1 (es) 2005-04-01
EP2008650A2 (en) 2008-12-31
AT501681B1 (de) 2012-04-15
US20190175527A1 (en) 2019-06-13
TW200503784A (en) 2005-02-01
DE122011100047I1 (de) 2011-12-15
DE202004021680U1 (de) 2010-04-22
RU2475236C2 (ru) 2013-02-20
TNSN05256A1 (en) 2007-07-10
ITMI20040682A1 (it) 2004-07-06
AR078781A2 (es) 2011-11-30
NO329332B1 (no) 2010-09-27
AT504853A2 (de) 2008-08-15
RU2005134173A (ru) 2006-09-10
KR101367574B1 (ko) 2014-02-25
LU91867I2 (fr) 2011-11-08
HK1155647A1 (en) 2012-05-25
AR078782A2 (es) 2011-11-30
CA2521325C (en) 2010-09-14
ES2228282B1 (es) 2006-02-16
NO20100250L (no) 2006-01-09
CA2707750A1 (en) 2004-10-21
AR043987A1 (es) 2005-08-17
NO334116B1 (no) 2013-12-16
WO2004089341A1 (en) 2004-10-21
AU2004228929B2 (en) 2008-02-07
US20080311188A1 (en) 2008-12-18
GB2400318A (en) 2004-10-13
NZ542622A (en) 2009-01-31
PL1613288T3 (pl) 2009-07-31
CA2521325A1 (en) 2004-10-21
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
PE20090743A1 (es) 2009-07-17
BRPI0409250B8 (pt) 2022-01-18
MXPA05010860A (es) 2006-05-25
EP1613288A1 (en) 2006-01-11
RU2358716C2 (ru) 2009-06-20
US20220031609A1 (en) 2022-02-03
US20130108675A1 (en) 2013-05-02
GB2400318B (en) 2005-08-10
DK1613288T3 (da) 2009-03-23
FR11C0036I2 (fr) 2023-12-29
DE602004017847D1 (de) 2009-01-02
IS8885A (is) 2010-02-25
BE2011C030I2 (Direct) 2023-03-07
ECSP056090A (es) 2006-03-01
IL197578A0 (en) 2011-07-31
EP1613288B1 (en) 2008-11-19
IS8114A (is) 2005-11-01
NO2011016I1 (no) 2011-09-19
EP2319502A1 (en) 2011-05-11
US20090203798A1 (en) 2009-08-13
US20140255497A1 (en) 2014-09-11
AT501681A1 (de) 2006-10-15
IL197578A (en) 2015-10-29
LU91867I9 (Direct) 2019-01-03
CL2004000745A1 (es) 2005-02-11
JP2013177404A (ja) 2013-09-09
FR11C0036I1 (fr) 2011-10-14
US20140011885A1 (en) 2014-01-09
EP2769713A1 (en) 2014-08-27
RU2010147000A (ru) 2012-08-10
FR2854073A1 (fr) 2004-10-29
RU2012148593A (ru) 2014-05-20
PE20131352A1 (es) 2013-11-14
CY2011013I2 (el) 2014-04-09
KR20120101148A (ko) 2012-09-12
CY2011013I1 (el) 2014-04-09
JP2004307506A (ja) 2004-11-04
MA27729A1 (fr) 2006-01-02
PE20050396A1 (es) 2005-07-05
AU2004228929A1 (en) 2004-10-21
TWI332847B (en) 2010-11-11
GB0407819D0 (en) 2004-05-12
IE20040246A1 (en) 2004-12-15
NZ586280A (en) 2011-12-22
KR20110005320A (ko) 2011-01-17
SG175449A1 (en) 2011-11-28
US20170290787A1 (en) 2017-10-12
NO335120B1 (no) 2014-09-22
NO20055231D0 (no) 2005-11-07
CN101797241A (zh) 2010-08-11
GR1005052B (el) 2005-11-30
PT1613288E (pt) 2009-02-25
HRP20100601A2 (hr) 2011-03-31
RU2009105403A (ru) 2010-08-27
ZA200507394B (en) 2007-03-28
KR20050121712A (ko) 2005-12-27
PE20150676A1 (es) 2015-05-17
SI1613288T1 (sl) 2009-04-30
US20110105620A1 (en) 2011-05-05
CY1110260T1 (el) 2014-04-09
BRPI0409250A (pt) 2006-03-28
US20060275357A1 (en) 2006-12-07
CY1117071T1 (el) 2017-04-05
PE20130200A1 (es) 2013-03-09
RU2475237C2 (ru) 2013-02-20
ES2320767T3 (es) 2009-05-28
ATE414508T1 (de) 2008-12-15
HK1091114A1 (en) 2007-01-12
HRP20050886A2 (en) 2006-11-30
JP2011006461A (ja) 2011-01-13
HUE028247T2 (en) 2016-12-28
NO20131287L (no) 2006-01-09
SI2316431T1 (sl) 2016-04-29
JP5495467B2 (ja) 2014-05-21
RU2010146697A (ru) 2012-05-27
CN101797241B (zh) 2013-03-27
EP2316431A1 (en) 2011-05-04
HK1071685A1 (en) 2005-07-29

Similar Documents

Publication Publication Date Title
FR2854073B1 (fr) Composition pharmaceutique solide comprenant un agoniste du recepteur s1p et un alcool de sucre
DK1185253T3 (da) Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac
NO20081218L (no) Flytende formuleringer
DE60131703D1 (de) Orale feste pharmazeutische Zusammensetzungen zur pH-abhängig mehrphasigen Freisetzung
FR2850576B1 (fr) Composition comprenant un melange de principes actifs, et procede de preparation
EP1648697A4 (en) METHOD FOR INCREASING CAPACITY IN AN AUTOMATIC CLINICAL ANALYZER BY USING A MODULAR REAGENT ABUTMENT
CO5580741A2 (es) Composicion farmaceutica que comprende un agonista de receptor de 5ht1
FR2867682B1 (fr) Composition pharmaceutique anhydre associant un agent silicone et un principe actif solubilise.
WO2008060546A3 (en) Oral formulations
NO20064808L (no) Orale matrixformuleringer med licarbazepin
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
NO20064783L (no) Opplosningstabeletter med licarbazepin
庞炜 Implications of Student-Centered Approach for College English Teaching
TH87290A (th) สารองค์ประกอบทางเภสัชกรรมชนิดใหม่ที่ประกอบด้วยเลเวไทราซีแทม และกระบวนการสำหรับการเตรียมสารนั้น
DK1847259T3 (da) Polyxamerer som smøremiddel til farmaceutiske sammensætningen indeholdende thieno[3,2-c]pyridin-derivater

Legal Events

Date Code Title Description
CA Change of address

Effective date: 20130703

CD Change of name or company name

Owner name: MITSUBISHI TANABE PHARMA CORPORATION, JP

Effective date: 20130703

Owner name: NOVARTIS AG, CH

Effective date: 20130703

TQ Partial transmission of property

Owner name: MITSUBISHI TANABE PHARMA CORPORATION, JP

Effective date: 20130703

Owner name: NOVARTIS AG, CH

Effective date: 20130703

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20